Natera reported outstanding Q1 2023 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. The company's product revenues witnessed a ...
Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3% Natera’s study is the largest clinical validation of a fetal RhD ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at ...
Natera (NTRA) announced that Obstetrics & Gynecology published the company’s clinical validation study on its cell-free DNA, or cfDNA, Fetal RhD noninvasive prenatal test. Natera’s study is the ...
FIRST ON FOX: A tech watchdog has filed a complaint letter with the Securities and Exchange Commission (SEC), alleging that biotech firm Natera misled the public about its prenatal screening ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results